In 40 seconds
MS fatigue affects up to 80% of patients and is often the most disabling symptom. The 2025 PEMF-fatigue meta-analysis (7 RCTs / n=327) found a small but significant reduction in fatigue (SMD −0.23) — no benefit on quality of life or depression. Lappin 2003 (n=117) and Piatkowski 2009 (n=37, BEMER) were positive; Mostert 2005 and the 2022 Brazilian whole-body PEMF RCT (n=44) were null. Standard MS-fatigue management (energy conservation, exercise, sleep optimisation, treatment of depression and thyroid screen) remains first-line per NICE NG220. PEMF may be a modest adjunct in selected patients; it is not a substitute for the standard pathway.
Quick facts
- Prevalence: Up to 80% of MS patients
- 2025 PEMF meta-analysis: SMD −0.23 across 7 RCTs (n=327)
- Positive trials: Lappin 2003 (n=117), Piatkowski 2009 BEMER (n=37)
- Null trials: Mostert 2005 (n=25), Brazilian 2022 (n=44)
- NICE NG220 first-line: Energy conservation, exercise, sleep, depression screen
- rTMS-fatigue evidence: Smaller; deep TMS Gaede 2018 showed trend, underpowered
- Stop rule: If FSS/MFIS not improved at 4-8 weeks, stop
What the fatigue evidence shows
MS fatigue is the symptom most consistently studied with PEMF — and the picture is mixed. The 2025 meta-analysis pooling 7 RCTs (n=327) reported a small significant fatigue reduction (SMD −0.23) but no improvement in quality of life or depression. The aggregate signal is real but modest. Individual trials are inconsistent: Lappin 2003 (n=117, portable Enermed device) and Piatkowski 2009 (n=37, BEMER) showed significant fatigue reduction; Mostert 2005 (n=25, Santerra mattress) showed a non-significant 18% vs 7% reduction; the high-quality 2022 Brazilian RCT (n=44, whole-body 15-30 Hz mat) was completely null on fatigue, gait, depression and quality of life. Heterogeneity in device, protocol and patient selection makes simple read-across impossible.
The NICE NG220 pathway for MS fatigue centres on energy conservation, graded exercise, sleep optimisation, screening for depression and thyroid disease, and review of medications that can worsen fatigue. Amantadine and modafinil are sometimes prescribed off-licence. PEMF is not on this list and the MS Society UK notes the dearth of robust evidence.
If a patient and their MS team decide to trial home PEMF for fatigue, set the protocol up to measure: baseline FSS (Fatigue Severity Scale) or MFIS (Modified Fatigue Impact Scale), 4-8 week course, end-point reassessment, and a clear stop rule if no improvement.
Frequently asked questions
Does PEMF actually help MS fatigue?
The 2025 meta-analysis of 7 RCTs (n=327) found a small significant benefit (SMD −0.23). Individual trials are mixed. The benefit if present is modest, not transformative.
Which PEMF device has the best evidence?
BEMER (Piatkowski 2009) and Enermed (Lappin 2003) have the published trial evidence. Newer whole-body 15-30 Hz mats have at least one negative high-quality trial (Brazilian 2022).
Is amantadine more evidence-based than PEMF?
Amantadine and modafinil have NICE-noted but limited evidence; both are off-licence for MS-fatigue. Aggregate evidence is comparable in magnitude to PEMF — small effect sizes.
How long should I trial PEMF for fatigue?
4-8 weeks with objective measurement (FSS or MFIS at baseline and end). Stop if no clinically meaningful change.
Does exercise beat PEMF for MS fatigue?
Exercise has consistently larger effect sizes than PEMF in MS-fatigue trials. The 'paradoxical' finding that more activity reduces fatigue in MS is well-established.
Will PEMF worsen my MS via Uhthoff?
Some devices generate mild local warmth. If you notice symptom flare with use, stop. Most patients tolerate without issues.
Can I combine PEMF with modafinil?
No known interaction. Both can be tried sequentially or together with the MS team's awareness.
What does the MS Society say?
The MS Society UK notes there is little robust evidence for magnetic field therapy in MS.
Related pages
Looking for a PEMF clinic in the UK?
We list every credible PEMF therapy provider in the UK. No UK clinic can legally claim to treat MS with PEMF or rTMS.